Current Price{{movement}} ${{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{marketstatus.OPEN ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Tyrian Diagnostics Limited (TDX)
is a publicly listed company on the Australian Securities Exchange (ASX).


General Overview

About Tyrian Diagnostics


Tyrian Diagnostics is an ASX-listed company that has discovered and validated novel biomarkers for tuberculosis and developed a proprietary point of care diagnostics platform, DiagnostIQTM.

The Company is currently pursuing the licensing and sale of its core intellectual property assets, including its DiagnostIQ technology and TB biomarker patents, while also considering alternative strategic options.


Tyrian's Technology

TDXTyrian Diagnostics has in the past developed proprietary technology for rapid diagnosis. This technology can be applied in a wide range of diagnostic fields including medical, animal health, food and environmental testing. The technology has been reduced to commercial practice through a rapid test for determining wheat quality, marketed by Bayer Crop Science as ReadRiteTM. Bayer Crop Science has an ongoing licence from Tyrian for use of its technology in this product.

Tyrian's technology consists of a small disposable plastic capsule, the DiagnostIQ device, in which tests are carried out, and a USB-driven Reader machine which can be used to assess results precisely. Results can also be determined qualitatively by comparing the results of a test on a standard colour chart. DiagnostIQ is distinguished by its speed (results in 5 minutes), reliability and unique patent position. It is ideally positioned for use in the field, factory or physician's office because of its simplicity and ease of use. Both the Reader and device are manufactured at commercial scale.

Tyrian has proprietary markers for the diagnosis of active tuberculosis. The use of these markers for development of a molecular test but not a protein-based test for active TB was licensed to SpeeDx Pty Ltd in 2011.

Tyrian Diagnostics ceased its research and development operations, terminating all employees, in November, 2011, and is seeking licensees of its technology for application in relevant fields. The company continues to operate as a manager and licensor of intellectual property and to explore options for the ongoing activities of the company. Please see the Contacts page to follow up on either of these areas.

Contact Info

Tyrian Diagnostics Limited

Level 10
167 Macquarie Street
Sydney, NSW
AU Australia, 2000

Phone: +61 2 8231 6646
Fax: +61 2 9973 3189

Click here to view the interactive map
Tyrian Diagnostics Limited Google Map
Tyrian Diagnostics Limited Google Map

Share Registry

Link Market Services Limited - Click here to view share registry profile

Phone: +61 2 8280 7100
Fax: N/A

Level 12
680 George Street
Sydney, NSW
AU Australia, 2000

Important Information

The General Overview, Services, Products and Projects information for this profile was last edited on 04 Jun 2015.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.




Report a bug